MORE►
Cowtown Angels
Premature babies diagnosed with bronchopulmonary dysplasia (BPD) face the risk of rehospitalization, delayed brain development, and respiratory problems throughout childhood. No FDA-approved therapies are available for BPD—which is why the new FDA designation for AyuVis's drug candidate, AVR-48, could lead to game-changing impact.
Fort Worth’s AyuVis Gets FDA Fast‑Track Designation for Its Drug for Babies with a Chronic Lung Disease
by David Seeley | Aug 23, 2024
Premature babies diagnosed with bronchopulmonary dysplasia (BPD) face the risk of rehospitalization, delayed brain development, and respiratory problems throughout childhood. No FDA-approved therapies are available for BPD—which is why the new FDA designation for AyuVis's drug candidate, AVR-48, could lead to game-changing impact.
by David Seeley |
Oct 6, 2023
TechFW's Impact Showcase "embodied the spirit of innovation, the essence of progress, and the promise of a better tomorrow" at Dickies Arena's
Simmons Bank Pavilion Thursday in Fort Worth.
MORE►
by Lance Murray |
May 17, 2023
The grant from the National Heart, Lung, and Blood Institute will fund a first-in-human Phase 1 clinical trial of a new generation of immunotherapies. This is the fourth NIH grant AyuVis has received since its founding in 2014, doubling total non-dilutive funding to $4.2 million. Co-Founder and CEO Dr. Suchismita Acharya calls the move to a human trial "a huge milestone for AyuVis."
MORE►
by Kevin Cummings |
May 12, 2022
AyuVis, an immunotherapy startup, is set to get a $1.8 million Small Business Innovation Research grant from the Eunice Kennedy Shriver National Institute of Child Health and Human Development. The funding will support the pre-clinical research of its drug candidate to treat the second-leading cause of death in premature babies.
Founder Suchismita Acharya calls the timing "perfect."
Founder Suchismita Acharya calls the timing "perfect."
MORE►
![At the Fourth Annual iC3 Life Science Summit at UT Arlington on Oct. 10, 2017 recipient Lyda Hill will present the award. To register for the summit, visit www.bionorthtx.org. [Illustration: bestbrk/istockphoto]](https://s24806.pcdn.co/wp-content/uploads/2018/09/Bionorthconcept_970_bestbrk_istockphotovector-molecule-background-genetic-and-chemical-compounds-abstract-vector-id908258902-940x436.jpg)
[Illustration: bestbrk/istockphoto]
BionorthTX to Award Darlene Boudreaux With 2018 Dennis K. Stone Award
by Alex Edwards | Sep 27, 2018
2017 recipient Lyda Hill will present the award at the fourth annual iC3 Life Science Summit at UT Arlington on Oct. 10.
MORE►
by Jewels Clark |
Dec 22, 2017
The Austin-based app was developed four years ago, and today it's used in 65 cities in the U.S., Australia, Canada, England, Hong Kong, Mexico, and Spain.
MORE►
by Julia Batlle |
Apr 12, 2017
Art Clapp is continuing his pharmaceutical endeavors with a new product from his company, NuvoThera.
MORE►
by Nicholas Sakelaris |
Jan 27, 2017
The Swiss pharmaceutical company paid $465 million for the Fort Worth eye care startup.
MORE►
